Hello,
Welcome to Insider Healthcare. I'm healthcare editor Leah Rosenbaum, and today in healthcare news:
- UnitedHealth has a new plan to partner with hospital systems;
- A highly anticipated boosters trial found that J&J shot recipients got a better immune response with Pfizer and Moderna;
- Merck could make billions of its COVID-19 pill.
If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or tweet @leah_rosenbaum. Let's get to it…
Optum CEO Andrew Witty
Reuters
UnitedHealth has made a fortune from its sprawling network of doctors and clinics. Now it's setting its sights on hospitals.
Reuters
- UnitedHealth Group has made a fortune owning medical clinics and keeping patients out of hospitals.
- But the healthcare giant is increasingly looking at hospitals as a source of revenue.
- Last week, UnitedHealth struck a deal with health system SSM Health to handle back-office operations.
A vial of Johnson & Johnson (Janssen's) Covid-19 vaccine.
Eduardo Sanz/Europa Press via Getty Images
Scientists gave J&J vaccine recipients different booster shots in a highly anticipated trial, and found they got a much better immune response with Moderna and Pfizer
Eduardo Sanz/Europa Press via Getty Images
- People who got the J&J vaccine may get a better immune response from a Moderna or Pfizer booster, a major new study suggests.
- J&J recipients generated far more antibodies after a Moderna or Pfizer shot, instead of a second J&J jab.
- However, higher levels of antibodies do not necessarily mean a person is more protected from the coronavirus.
Molnupiravir is an experimental oral antiviral developed by Merck and Ridgeback Biotherapeutics that could treat COVID-19
Merck
Merck is set to make billions off a COVID-19 pill that could change the pandemic. Here's why some countries will pay more than others.
Merck
- Merck's COVID-19 pill holds tremendous promise in fighting the pandemic.
- Industry analysts expect Merck to make billions off the not-yet-authorized drug.
- Some countries will be paying $12 per patient, while the US agreed to pay $712 per treatment course.
More stories we're reading:
- Fully vaccinated people who previously had COVID-19 should be last in line for booster shots, experts say (Insider)
- This online pharmacy sold millions of dollars of Ivermectin to desperate patients (TIME)
- A drugmaker backed by the company that owns Marlboro cigarettes plans to launch the world's first plant-based COVID-19 vaccine (Insider)
- COVID-19 has killed hundreds of police officers, but many still refuse to get vaccinated (The New York Times)
-Leah
Read the original article on Business Insider